Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma

摘要: Food and Drug Administration-approved treatment for metastatic melanoma, including interferon alpha interleukin-2, offer a modest benefit. Immunotherapy, although has not enjoyed high overall response rates, is capable of providing durable responses in subset patients. In recent years, new molecular-targeted therapies have become available promise clinical benefit, low durability response. It yet clear how best to integrate these 2 novel modalities that target the immune melanoma (immune therapy) or molecular signaling pathways cells (targeted therapy). Many signal transduction are important both tumor cell T-cell proliferation survival, which generate risk combining targeted therapy immunotherapy. This review focuses on role immunotherapy discusses combine rationally increased duration